Patenting and Pricing Eliquis, Ozempic, and Other Medicare-Targeted Drugs

If you need assistance accessing the link, please email info@thecapitolforum-news.com.

Tahir will discuss I-MAK’s new report, “Overpatented, Overpriced,” which reveals the systemic flaws in America’s drug patent system. He’ll also describe findings from I-MAK’s recently updated Drug Patent Book database, particularly as they relate to Eliquis and the semaglutide-based drugs Ozempic, Rybelsus, and Wegovy.

Join us to learn more about:

• Patent term extensions and the billions they generate for blockbuster drugs
• How “patent thickets” and litigation strategies delay generic entry
• The stark pricing differences between U.S. drugs and international equivalents
• Why the Inflation Reduction Act is only a partial solution to the problem
• What systemic patent reform might look like

Tahir Amin Bio

Tahir Amin, LL.B., Dip. LP., is the Chief Executive Officer of the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit organisation working to address structural inequities in how medicines are developed and distributed. He has over 25 years of experience in intellectual property (IP) law, during which he has practised with two of the leading IP law firms in the United Kingdom and served as IP Counsel for multinational corporations. His work focuses on re-shaping IP laws and the related global political economy to better serve the public interest, by changing the structural power dynamics that allow health and economic inequities to persist.

Amin and I-MAK also put out a 10-point plan for the Biden-Harris administration to bring equity into the patent system, and their work was highlighted in an endorsement of patent reform from the New York Times Editorial Board. Amin is a former Harvard Medical School Fellow in the Department of Global Health & Social Medicine and TED Fellow. He has served as legal advisor/consultant to many international groups.